Drug Trial Radar · NCT00285766
Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression
Last checked: Nov 20, 2026Latest source record: Apr 22, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Aug 2002
Primary completion
Not stated
Study completion Jul 2005
Sponsor
- Lead sponsor
- Somerset PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 2, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objective of this 16-week, open-label study is to assess the safety and tolerability of once daily application of three doses of STS during continuous dosing in the treatment of elderly subjects with major depression. Subjects will have study visits (clinic visits) at beginning of study (baseline) and study weeks 1, 3, 5, 8, 12, and 16.
Conditions
- Major Depression
Interventions
Selegiline Transdermal SystemDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Mohammed Bari, M.D.
Chula Vista, California
Charles Meredith, M.D.
San Diego, California
Daniel Zimbroff, M.D.
Upland, California
Kathleen Toups, M.D.
Walnut Creek, California
Abbey Strauss, M.D.
Boynton Beach, Florida
Barry Baumel, M.D.
Miami Beach, Florida
Margarita Nunez, M.D.
St. Petersburg, Florida
Mildred Farmer, M.D.
St. Petersburg, Florida
Larry Eisner, M.D.
Tamarack, Florida
Andrew Cutler, M.D.
Winter Park, Florida
Robert Riesenberg, M.D.
Atlanta, Georgia
James Hartford, M.D.
Florence, Kentucky
Mitchel Kling, M.D.
Baltimore, Maryland
Louise Beckett, M.D.
Oklahoma City, Oklahoma
Penny Barnhart, M.D.
Wichita Falls, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.